|
1
|
Tsai CL, Koong AC, Hsu FM, Graber M, Chen
IS and Cheng JC: Biomarker studies on radiotherapy to
hepatocellular carcinoma. Oncology. 84(Suppl 1): 64–68. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Psyrri A, Arkadopoulos N, Vassilakopoulou
M, Smyrniotis V and Dimitriadis G: Pathways and targets in
hepatocellular carcinoma. Expert Rev Anticancer Ther. 12:1347–1357.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
D’Andrea S, Berton S, Segatto I, Fabris L,
Canzonieri V, Colombatti A, Vecchione A, Belletti B and Baldassarre
G: Stathmin is dispensable for tumor onset in mice. PLoS One.
7:e455612012.PubMed/NCBI
|
|
5
|
Chen J, Abi-Daoud M, Wang A, Yang X, Zhang
X, Feilotter HE and Tron VA: Stathmin 1 is a potential novel
oncogene in melanoma. Oncogene. 32:1330–1337. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tian X, Tian Y, Sarich N, Wu T and
Birukova AA: Novel role of stathmin in microtubule-dependent
control of endothelial permeability. FASEB J. 26:3862–3874. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nemunaitis J: Stathmin 1: a protein with
many tasks. New biomarker and potential target in cancer. Expert
Opin Ther Targets. 16:631–634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gan L, Guo K, Li Y, Kang X, Sun L, Shu H
and Liu Y: Up-regulated expression of stathmin may be associated
with hepatocarcinogenesis. Oncol Rep. 23:1037–1043. 2010.PubMed/NCBI
|
|
9
|
Belletti B and Baldassarre G: Stathmin: a
protein with many tasks. New biomarker and potential target in
cancer. Expert Opin Ther Targets. 15:1249–1266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Long M, Yin G, Liu L, Lin F, Wang X, Ren
J, Wei J, Dong K and Zhang H: Adenovirus-mediated Aurora A shRNA
driven by stathmin promoter suppressed tumor growth and enhanced
paclitaxel chemotherapy sensitivity in human breast carcinoma
cells. Cancer Gene Ther. 19:271–281. 2012. View Article : Google Scholar
|
|
11
|
Sabherwal Y, Mahajan N, Helseth DL,
Gassmann M, Shi H and Zhang M: PDEF downregulates stathmin
expression in prostate cancer. Int J Oncol. 40:1889–1899.
2012.PubMed/NCBI
|
|
12
|
Wang X, Chen Y, Han QB, Chan CY, Wang H,
Liu Z, Cheng CH, Yew DT, Lin MC, He ML, Xu HX, Sung JJ and Kung HF:
Proteomic identification of molecular targets of gambogic acid:
role of stathmin in hepatocellular carcinoma. Proteomics.
9:242–253. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen YL, Uen YH, Li CF, Horng KC, Chen LR,
Wu WR, Tseng HY, Huang HY, Wu LC and Shiue YL: The E2F
transcription factor 1 transactives stathmin 1 in hepatocellular
carcinoma. Ann Surg Oncol. 20:4041–4054. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hsieh SY, Huang SF, Yu MC, et al:
Stathmin1 overexpression associated with polyploidy, tumor-cell
invasion, early recurrence, and poor prognosis in human hepatoma.
Mol Carcinog. 49:476–487. 2010.PubMed/NCBI
|
|
15
|
Singer S, Ehemann V, Brauckhoff A, Keith
M, Vreden S, Schirmacher P and Breuhahn K: Protumorigenic
overexpression of stathmin/Op18 by gain-of-function mutation in p53
in human hepatocarcinogenesis. Hepatology. 46:759–768. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen Y, Lin MC, Yao H, Wang H, Zhang AQ,
Yu J, Hui CK, Lau GK, He ML, Sung J and Kung HF:
Lentivirus-mediated RNA interference targeting enhancer of zeste
homolog 2 inhibits hepatocellular carcinoma growth through
down-regulation of stathmin. Hepatology. 46:200–208. 2007.
View Article : Google Scholar
|
